IMB-002 / Immunobiome - LARVOL DELTA

Korean companies set high expectations for microbiome industry (Korea Biomedical Review) - "...the IMB002 drug candidate which submitted its phase 1 clinical trial IND for treating inflammatory bowel disease (IBD) at the beginning of the year and is expected to be completed by the second quarter of this year."

New P1 trial • Immunology • Inflammatory Bowel Disease

ImmunoBiome (BIO 2022) - "Based on our solid scientific infrastructures (Germ-Free mouse facility), qualified scientist (Immunologist and AI specialist), and merits of academic research environment (located in POSTECH campus), we could accelerate the development process and publish papers in prestigious academic journals. Currently, we are developing two LBP candidates, IMB001 and IMB002, targeting cancer and inflammatory disorders."

Immunology • Inflammation • Oncology

Immunobiome’s strategy to challenge ’microbiome anticancer drug’? [Google translation] (Biospectator) - "Another lead program is IMB-002, a single strain treatment candidate targeting Inflammatory Bowel Disease...and aims to enter phase 1 clinical trials in the fourth quarter of 2022...When the cell surface polysaccharide of IMB-002 (Cell Surface β-glucan/galactan) was treated in a rat model of inflammatory bowel disease, it suppressed the weight loss in the rats compared to the control group and prevented the decrease in intestinal length."

New P1 trial • Preclinical • Inflammatory Bowel Disease